<DOC>
	<DOCNO>NCT02771626</DOCNO>
	<brief_summary>This study open-label Phase 1/ 2 evaluation CB-839 combination nivolumab patient clear cell renal cell carcinoma , melanoma , non-small cell lung cancer .</brief_summary>
	<brief_title>Study CB-839 Combination With Nivolumab Patients With ccRCC Other Solid Tumors</brief_title>
	<detailed_description>This study open-label Phase 1/ 2 evaluation CB-839 combination nivolumab patient clear cell renal cell carcinoma , melanoma , non-small cell lung cancer . During Phase 1 , patient enrol escalate dose cohort determine recommend phase 2 dose ( RP2D ) . In Phase 2 , patient clear cell renal cell carcinoma , melanoma , non-small cell lung cancer enrol separate cohort . All patient assess safety , pharmacokinetics , biomarkers tumor response .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Addition eligibility criterion base tumor type apply Ability provide write informed consent accordance federal , local , institutional guideline Histological cytological diagnosis metastatic cancer locally advance cancer amenable local therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Life Expectancy least 3 month Adequate hepatic , renal , cardiac , hematologic function Measurable disease RECISTv1.1 criterion Resolution treatmentrelated toxicity except alopecia Unable receive oral medication Unable receive oral IV hydration Intolerance prior antiPD1/PDL1 therapy Prior severe hypersensitivity reaction another monoclonal antibody ( mAb ) Any current previous malignancy within 3 year except protocol allow malignancy Chemotherapy , Tyrosine Kinase Inhibitor therapy , radiation therapy hormonal therapy within 2 week Immunotherapy biological therapy , investigational agent within 3 week ( Note : Some cohort exception allow antiPD1 therapy ) Active know suspect exclusionary autoimmune disease Any condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) systemic immunosuppressive medication within 2 week History known risk factor bowel perforation Symptomatic ascites pleural effusion Major surgery within 28 day Cycle 1 Day 1 Active infection require within 2 week prior first dose study drug Patients HIV , Hepatitis B C Conditions could interfere treatment protocolrelated procedure Active , nonstable brain metastasis CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RCC</keyword>
	<keyword>MEL</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Immuno-Oncology</keyword>
	<keyword>Tumor Metabolism</keyword>
	<keyword>Glutaminase</keyword>
	<keyword>Glutaminase Inhibitor</keyword>
</DOC>